Ann: Positive IHL-675A in vivo results and FDA Pathway, page-87

Spot on MM , we are at the first rung here . The company has only just started its rise to a significant biotech .The application on the drug will be significant as they will as they foreshadow extend the patent to cover other inflammatory conditions . It is a really exciting start with exponential potential here .
I have invested on some crackers this year ADN , 3DA but I rate the potential of this company higher and it is yet to explode but imo it will .
I am looking forward to the BOD developing and announcing results on the trials and progressing its strategy . Very happy so far the BOD has not put a foot wrong very professional and know what they are doing .